TScan Therapeutics (TCRX) Corporate presentation summary

Strategic focus and pipeline overview

• Advancing TCR-T cell therapies for hematologic malignancies, solid tumors, and autoimmune diseases, with clinical, preclinical, and discovery-stage programs targeting high unmet needs.

• Lead heme program (TSC-101) targets residual disease post-allogeneic HCT in AML/MDS, showing favorable relapse-free and overall survival with no dose-limiting toxicities.

• Solid tumor program developing multiplex TCR-T therapies to address tumor heterogeneity, with in vivo engineering platform in preclinical development.

• Autoimmunity program leverages proprietary TargetScan platform to identify disease-driving autoantigens, with collaborations for Crohn's disease and targets identified in multiple indications.

• $152.4M in cash as of Dec 31, 2025, funding operations into H2 2027.

Heme malignancy program: clinical progress and market opportunity

• TSC-101 demonstrated durable responses, with 100% of patients relapse-free at 2 years post-HCT in initial cohorts.

• ALLOHA Phase 1 trial showed TSC-101 is well tolerated, with no dose-limiting toxicities and manageable adverse events.

• Pivotal trial for TSC-101 to launch in Q2 2026, using a biologically assigned control arm and relapse-free survival as the primary endpoint.

• Addressable U.S. market at launch estimated at 2,100 patients, with $1.4B+ peak revenue potential; global expansion possible with additional HLA-targeted products.

• Commercial-ready manufacturing process reduces production time and supports scalability.

Solid tumor and autoimmunity pipeline

• Multiplex TCR-T therapies in development to overcome solid tumor heterogeneity, aiming for durable responses and potential cures.

• In vivo lentiviral engineering platform under development to enable off-the-shelf TCR-T therapies, reducing costs and manufacturing time.

• TargetScan platform has identified novel autoantigens in systemic sclerosis, ulcerative colitis, ankylosing spondylitis, and birdshot uveitis.

• Collaboration with Amgen for target discovery in Crohn's disease.